Quince Therapeutics Inc (QNCX) Stock Price, Quote & News

Company Profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an aut...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 910 5717

Website: www.quincetx.com

Address:

611 Gateway Boulevard, Suite 273, South San Francisco, United States

BuIIflow Jan. 16 at 11:20 PM

Quince Therapeutics $QNCX Call Flow was posted in the Swing-Flow Channel in Discord on Monday. This small cap stock exploded +23% only 4 days later. That's a 130% Gain on these contracts 🚀

0 · Reply

Diamond_Playz Jan. 16 at 9:49 PM

Fox has been ahead of the curve on a bunch of picks, and it's paid off for me! 💎 Hit that FOLLOW on @ReversalFox – One of the best traders know ⭐ Can see more on $CTMX $KWM $SJ $QNCX +

0 · Reply

bullval1 Jan. 16 at 9:44 PM

$QNCX Bridgeway Capital Management LLC raised its holdings in shares of Quince Therapeutics by 20.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company's stock valued at $212,000 after purchasing an additional 22,200 shares in the last quarter. Nantahala Capital Management LLC purchased a new stake in shares of Quince Therapeutics during the 2nd quarter worth $4,172,000. Vanguard Group Inc. increased its holdings in Quince Therapeutics by 21.3% in the third quarter. Vanguard Group Inc. now owns 1,763,387 shares of the company's stock valued at $2,874,000 after buying an additional 309,349 shares during the last quarter. Finally, Millennium Management LLC raised its stake in Quince Therapeutics by 1,152.9% in the third quarter. Millennium Management LLC now owns 1,386,776 shares of the company's stock valued at $2,260,000 after buying an additional 1,276,094

0 · Reply

Sunspotter1 Jan. 16 at 8:02 PM

$QNCX looks like the cavalry showed up today...here we go, galloping to the prize.

1 · Reply

ActaVerba Jan. 16 at 7:44 PM

$QNCX So close now to the big day

0 · Reply

JuggernautRaider Jan. 16 at 7:26 PM

$QNCX what have here?? QUINCE Therapeutics?

0 · Reply

AdamantiumBull Jan. 16 at 7:25 PM

$QNCX Geeze, what lit a fire under this one's ass today?

2 · Reply

Stringbag Jan. 16 at 7:00 PM

$QNCX bought

0 · Reply

hitmongreen Jan. 16 at 6:27 PM

$QNCX looking good here

0 · Reply

prismmarketview Jan. 16 at 5:28 PM

PRISM Mid-Day Movers: Beauty & Wellness and Biotech are Today’s Leaders. Venus Concept (NASDAQ: $VERO) is rocketing more than 600% on heavy volume after a new 13D filing stoked going‑private and change‑of‑control speculation, even as the medical aesthetics and hair‑restoration device maker’s market cap remains in the low single‑digit millions. Quince Therapeutics (NASDAQ: $QNCX) is grinding higher in the high‑$2S to low‑$3S, now up about 25–30% over the past month and roughly 170% over the last year as traders focus on its AIDE‑enabled eDSP corticosteroid‑in‑red‑blood‑cells program targeting rare skeletal and neuromuscular diseases. Other Notable Movers: Tigo Energy ( $TYGO) up 21% Aditxt Inc. ( $ADTX) up 18% PAVmed Inc.( $PAVM) down -24% prismmarketview.com/prism-m...

0 · Reply

Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential

Dec 15, 2025, 8:00 AM EST - 4 weeks ago

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia

Dec 10, 2025, 4:05 PM EST - 5 weeks ago

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

Nov 24, 2025, 8:00 AM EST - 7 weeks ago

Quince Therapeutics to Participate at Investor Events in December 2025

Nov 12, 2025, 4:05 PM EST - 2 months ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 4:05 PM EST - 2 months ago

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Oct 9, 2025, 4:05 PM EDT - 3 months ago

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Oct 2, 2025, 5:12 PM EDT - 3 months ago

Quince Therapeutics, Inc. (QNCX) Analyst/Investor Day Transcript

Sep 25, 2025, 4:05 PM EDT - 4 months ago

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Sep 24, 2025, 1:13 AM EDT - 4 months ago

Quince Therapeutics, Inc. - Special Call

Sep 11, 2025, 4:05 PM EDT - 4 months ago

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

Sep 2, 2025, 4:05 PM EDT - 4 months ago

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 11, 2025, 4:05 PM EDT - 5 months ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 8:00 AM EDT - 5 months ago

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

OPCH

Jul 16, 2025, 8:00 AM EDT - 6 months ago

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Jul 10, 2025, 4:05 PM EDT - 6 months ago

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Jun 25, 2025, 4:05 PM EDT - 7 months ago

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

Jun 18, 2025, 4:05 PM EDT - 7 months ago

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Jun 12, 2025, 5:15 PM EDT - 7 months ago

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Jun 3, 2025, 4:05 PM EDT - 8 months ago

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

May 15, 2025, 9:50 AM EDT - 8 months ago

Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026

May 13, 2025, 8:00 AM EDT - 8 months ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 9 months ago

Quince Therapeutics to Present at Citizens Life Sciences Conference

Apr 3, 2025, 4:05 PM EDT - 10 months ago

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 4:05 PM EDT - 10 months ago

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Feb 7, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Feb 5, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Jan 28, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Jan 27, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Jan 23, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Nov 13, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Nov 11, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Oct 14, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Participate at Upcoming Investor Conferences

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 19, 2024, 9:16 PM EDT - 1 year ago

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

May 13, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 6, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Feb 22, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Launches Scientific Advisory Board

Feb 15, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Feb 7, 2024, 4:05 PM EST - 2 years ago

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 4, 2024, 4:05 PM EST - 2 years ago

Quince Therapeutics to Participate at Investor Events in January 2024

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

Sep 28, 2023, 4:05 PM EDT - 2 years ago

U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia

BuIIflow Jan. 16 at 11:20 PM

Quince Therapeutics $QNCX Call Flow was posted in the Swing-Flow Channel in Discord on Monday. This small cap stock exploded +23% only 4 days later. That's a 130% Gain on these contracts 🚀

0 · Reply

Diamond_Playz Jan. 16 at 9:49 PM

Fox has been ahead of the curve on a bunch of picks, and it's paid off for me! 💎 Hit that FOLLOW on @ReversalFox – One of the best traders know ⭐ Can see more on $CTMX $KWM $SJ $QNCX +

0 · Reply

bullval1 Jan. 16 at 9:44 PM

0 · Reply

Sunspotter1 Jan. 16 at 8:02 PM

$QNCX looks like the cavalry showed up today...here we go, galloping to the prize.

1 · Reply

ActaVerba Jan. 16 at 7:44 PM

$QNCX So close now to the big day

0 · Reply

JuggernautRaider Jan. 16 at 7:26 PM

$QNCX what have here?? QUINCE Therapeutics?

0 · Reply

AdamantiumBull Jan. 16 at 7:25 PM

$QNCX Geeze, what lit a fire under this one's ass today?

2 · Reply

Stringbag Jan. 16 at 7:00 PM

$QNCX bought

0 · Reply

hitmongreen Jan. 16 at 6:27 PM

$QNCX looking good here

0 · Reply

prismmarketview Jan. 16 at 5:28 PM

0 · Reply

desibre Jan. 16 at 5:04 PM

$QNCX I don't know if people realize what kind of pathways does this trial open if it is successful.. If that is the case it would be almost impossible to predict a market cap this can reach in 5 years. Then it would be up to you to sell or ride throught the ups and downs until we(maybe) reach 10-15-20b or who knows what market cap!

0 · Reply

DiamondsPlayz Jan. 16 at 4:56 PM

For anyone looking to spot small-cap breakouts early, @ReversalFox is worth a FOLLOW . I’ve banked from many of his calls. 🚀 $SPHL $ADTX -- $QNCX $SXTP +

0 · Reply

RunningRobert1 Jan. 16 at 4:17 PM

$QNCX In all honesty its right were it should be before data I thought it would get to around a 200M Market cap and here we are

2 · Reply

ATNews Jan. 16 at 4:15 PM

$QNCX In the last 4 months, 9 institutions had purchased shares in this company - 0 had sold. This usually happens when a company is about to release good results.

0 · Reply

ATNews Jan. 16 at 4:12 PM

$QNCX Very bullish on this. Same people that alerted $CAPR before it shot up a crazy amount are now alerting $QNCX . This was also alerted much earlier to our group - head to our bio to join. We will reshare this post once QNCX goes to double digits.

1 · Reply

bingy329 Jan. 16 at 3:56 PM

$QNCX got lucky and loaded yesterday. bought the 2.5's, sold the 7.5's

0 · Reply

ACInvestorBlog Jan. 16 at 3:53 PM

$QNCX bingo !!

0 · Reply

Merlintrader Jan. 16 at 3:49 PM

$QNCX

0 · Reply

dixiebull Jan. 16 at 3:44 PM

$QNCX this guy, fire

0 · Reply

Cutlass Jan. 16 at 3:33 PM

$QNCX ✍️

0 · Reply

Sunspotter1 Jan. 16 at 3:29 PM

$QNCX let's see that data base lock PR 4:30pm today...whoa Nelly. I keep envisioning the Home Run scenario on the Ph3 data. Call me an optimist, but this trial has met very different standards than the last, primed for success. And then there's DMD, and the pipeline. Think IBD: Crohn's etc. those markets are absurdly sized and premium priced.

0 · Reply

bullval1 Jan. 16 at 3:27 PM

$QNCX Looking pretty good today, so far. We'll see if it's a head fake.

0 · Reply

Market Cap	167.60M
Revenue (ttm)	0.00
Net Income (ttm)	-56.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	16.53

Volume	2,855,300
Avg Vol	889,978
Day's Range	N/A - N/A
Shares Out	55.68M
Stochastic %K	54%
Beta	1.15
Analysts	Strong Sell
Price Target	$7.60